Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Investigational Treatment for the Disease

Both doses studied in this clinical trial led to statistically significant improvements across multiple measures of disease severity and demonstrated clear evidence of a dose-response.